N99-02: Melphalan and Buthionine Sulfoximine

Inclusion Criteria:

   - Patients have relapsed neuroblastoma and must have exhausted all other options for
   treatment before they can be considered for treatment on this study.

   - Relapsed patients who are greater than 6 months since having a stem cell transplant
   can enter on this study.

   - Patients must have stem cells collected and stored before starting treatment.

   - Patients must have a double lumen central venous line in place.

   - Patients must have adequate kidney and liver function measured by blood tests and test
   of renal function (creatinine clearance or glomerular filtration rate (GFR)).

   - Patients must have normal heart and lung function measured by lack of physical
   evidence or clinical history of difficulties breathing and tests of cardiac function
   (Echocardiogram or MUGA evaluation).

   - Patients must have an essentially normal neurological exam.

   - Patients must have one entire kidney that has not had any radiation at treatment
   doses. (Xrays and scans are ok).

   - Patients must have recovered from the effects of any prior treatment for their tumor.

Exclusion Criteria:

   - They have had any radiation therapy to the brain.

   - They have known history of or current tumor found in the brain or surrounding tissues.

   - They have a history of seizures.

   - They have a history of changes in a test of kidney function with antibiotic use in the
   6 months immediately before entering on this study.